Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (411-420 of 921) with videos related to

Pageof 93
Sort By:
European Urology Focus|July 30, 2017
Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate CancerPaolo Dell'Oglio, Mohamed Bishr, Katharina Boehm, et al.
European Urology|August 23, 2008
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy seriesHendrik Isbarn, Sascha A Ahyai, Felix K H Chun, et al.
European Urology|December 19, 2006
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mLAndrea Gallina, Claudio Jeldres, Felix K-H Chun, et al.
The Journal of Urology|October 19, 2010
Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trendsLars Budäus, Firas Abdollah, Maxine Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|December 27, 2011
Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomyMaxine Sun, Firas Abdollah, Marco Bianchi, et al.
BMC Cancer|March 2, 2026
Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohortMike Wenzel, Maximilian Filzmayer, Carolin Siech, et al.
European Journal of Cancer (Oxford, England : 1990)|February 13, 2007
Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screeningGeorg Hutterer, Paul Perrotte, Andrea Gallina, et al.
Scientific Reports|August 9, 2020
Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer propertiesSergey A Dyshlovoy, Moritz Kaune, Malte Kriegs, et al.
The Prostate|July 11, 2024
Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancerMike Wenzel, Nele Wagner, Benedikt Hoeh, et al.
European Urology|July 13, 2010
External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcomeMarco Auprich, Alexander Haese, Jochen Walz, et al.
Pageof 93

Showing results (411-420 of 921) with videos related to

Sort By:
Pageof 93
European Urology Focus|July 30, 2017
Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate CancerPaolo Dell'Oglio, Mohamed Bishr, Katharina Boehm, et al.
European Urology|August 23, 2008
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy seriesHendrik Isbarn, Sascha A Ahyai, Felix K H Chun, et al.
European Urology|December 19, 2006
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mLAndrea Gallina, Claudio Jeldres, Felix K-H Chun, et al.
The Journal of Urology|October 19, 2010
Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trendsLars Budäus, Firas Abdollah, Maxine Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|December 27, 2011
Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomyMaxine Sun, Firas Abdollah, Marco Bianchi, et al.
BMC Cancer|March 2, 2026
Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohortMike Wenzel, Maximilian Filzmayer, Carolin Siech, et al.
European Journal of Cancer (Oxford, England : 1990)|February 13, 2007
Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screeningGeorg Hutterer, Paul Perrotte, Andrea Gallina, et al.
Scientific Reports|August 9, 2020
Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer propertiesSergey A Dyshlovoy, Moritz Kaune, Malte Kriegs, et al.
The Prostate|July 11, 2024
Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancerMike Wenzel, Nele Wagner, Benedikt Hoeh, et al.
European Urology|July 13, 2010
External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcomeMarco Auprich, Alexander Haese, Jochen Walz, et al.
Pageof 93